TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A November 5, 2026, MedPage Today commentary describes chronic neuropathic pain as an underrecognized problem among ICU survivors and argues for earlier, more specific diagnosis. Its authors propose studying neuromodulation for selected patients, but say evidence from other pain conditions cannot establish that these treatments work after critical illness.
Six clinicians writing in MedPage Today on November 5, 2026, said chronic neuropathic pain deserves more attention among intensive care survivors and urged clinicians to distinguish it from other causes of persistent pain. Their accompanying review proposes studying neuromodulation for carefully selected patients, while acknowledging that its effectiveness after critical illness has not been established.
The authors cite a 2026 meta-analysis that estimated chronic pain incidence among ICU survivors at about 47% at three months, 29% at six months and 31% at 12 months. The estimates concern chronic pain overall, not neuropathic pain specifically, and vary across studies and follow-up periods. A separate systematic review found reported persistent-pain frequencies ranging from 28% to 77%, reflecting differences in populations and definitions.
In a prospective multicenter cohort of 814 patients, nearly 48% reported significant persistent pain three months after ICU admission. Among those reporting pain, about 9% screened positive for neuropathic pain symptoms. The authors stress that a positive screen is not, by itself, a definitive diagnosis, and that post-ICU pain should not automatically be classified as neuropathic.
Possible sources of pain include muscle injury, immobility, surgery, deconditioning and peripheral nerve damage. The commentary says rehabilitation, psychological support, sleep care and individualized medication remain central to recovery. Neuromodulation methods—including peripheral nerve stimulation, dorsal root ganglion stimulation and spinal cord stimulation—are presented as potential avenues for research when neuropathic symptoms remain disabling despite conventional care, not as established post-ICU treatments.
Why Pain Type Changes Recovery Care
Persistent pain can add to weakness, sleep problems and other difficulties faced by people recovering from critical illness. If pain is neuropathic, identifying the affected nerve or pattern may help clinicians choose more appropriate evaluation and care. The authors’ argument is not that every ICU survivor needs a pain procedure, but that more precise diagnosis may reveal a subgroup whose symptoms are not adequately addressed by general post-ICU rehabilitation or medication alone.
The distinction also matters because some medicines used for neuropathic pain can cause problems such as sedation, dizziness or cognitive effects, which may be especially difficult for patients with renal dysfunction or respiratory vulnerability. The commentary says medication decisions should be individualized; it does not establish that neuromodulation is safer or more effective for these patients. Any treatment choice requires clinical assessment by qualified professionals.
Products Worth Considering
BowFlex Results Series SelectTech Adjustable Dumbbells (Pair)
Therabody Theragun Relief Massage Gun – Black
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
From ICU Injury to Pain Research
Critical illness can affect nerves and muscles in different ways. The authors describe critical illness polyneuropathy as diffuse injury to motor and sensory nerves, which can involve weakness and altered sensation. Critical illness myopathy primarily affects muscle; weakness alone is not proof of neuropathic pain. Prolonged positioning or compression can also cause localized nerve injuries.
The review considers whether existing stimulation techniques might be studied according to a patient’s pain pattern and suspected injury. The authors point to trials involving other conditions: the ACCURATE trial reported higher three-month treatment success for dorsal root ganglion stimulation than conventional spinal cord stimulation among patients with lower-extremity complex regional pain syndrome or causalgia. The SENZA-PDN trial reported substantial pain relief with 10-kHz spinal cord stimulation in people with refractory painful diabetic neuropathy. Those results concern different conditions and cannot establish benefit for ICU survivors.
“We need to identify neuropathic pain earlier, understand its underlying mechanisms, and investigate treatment strategies beyond conventional pharmacotherapy when symptoms remain disabling.”
— The commentary’s authors
Evidence Gaps After Critical Illness
The supplied report does not establish how many ICU survivors have clinically confirmed chronic neuropathic pain, as distinct from broader persistent pain or positive screening results. Estimates also differ by study population, definition and time of follow-up. Further diagnostic work is needed to identify causes and determine which symptoms reflect nerve injury.
Most importantly, the authors say direct clinical evidence is insufficient to establish neuromodulation as a treatment for neuropathic pain after critical illness. Results from studies of complex regional pain syndrome, causalgia or diabetic neuropathy cannot be assumed to apply. The report does not specify whether trials in ICU survivors are underway, which patient groups would qualify, or what benefits and risks such trials might find.
Diagnosis Before Treatment Trials
The next step described by the authors is better recognition and characterization of neuropathic pain in ICU survivors, followed by research into therapies for patients whose symptoms remain disabling despite appropriate conventional care. A phenotype-based approach would match a treatment target to the patient’s identified pain pattern rather than treating post-ICU pain as a single condition.
The commentary does not announce a new clinical trial, guideline or change in standard care. Until direct evidence is available, neuromodulation remains a research possibility for this population, not a proven post-ICU treatment. Clinicians and patients will need evidence specific to critical illness before its benefits, risks and appropriate use can be determined.
Key Questions
How common is persistent pain after an ICU stay?
The figures cited in the commentary vary. A 2026 meta-analysis estimated chronic pain at about 47% at three months, 29% at six months and 31% at 12 months. These are estimates for chronic pain overall, not neuropathic pain specifically.
Does all pain after critical illness come from nerve damage?
No. Pain can be related to muscle injury, surgery, immobility, deconditioning or nerve damage. The authors say weakness alone does not establish neuropathic pain, and each patient’s symptoms require evaluation.
Is neuromodulation proven to treat pain in ICU survivors?
No. The authors describe peripheral nerve, dorsal root ganglion and spinal cord stimulation as possible research approaches. They say there is insufficient direct clinical evidence to establish their effectiveness after critical illness.
What should happen before considering a targeted treatment?
The commentary calls for better identification of the pain type and its likely source, alongside individualized recovery care. Treatment decisions, including medication or procedures, should be discussed with qualified clinicians who can assess a patient’s circumstances.
Source: medpagetoday.com
